$30 Billion Deal Collapses: Merck Terminates Acquisition Talks with Revolution Medicines

According to Reuters, citing media1Month25Reported on [date], Merck has terminated its partnership with cancer drug research and development company Revolution Medicines, Inc.Revolution MedicinesThe acquisition negotiations.

Sources revealed that the two parties failed to reach an agreement due to disagreements over price terms, causing the negotiations to stall. However, the report pointed out that it is possible that negotiations may resume in the future.Revolution MedicinesIt is also expected to attract other potential buyers.

Earlier this month, the media disclosed that Merck was in talks to acquireRevolution MedicinesConduct negotiations, with the transaction valuation initially set at280Hundreds of Millions to320Between billion US dollars.

If the transaction is successfully completed, Merck will obtainRevolution MedicinesExperimental drugs in the late-stage clinical trial phase under its umbrelladaraxonrasib, the drug has been approvedFDAThe granted Fast Track designation has significant clinical application potential.

According to the London Stock Exchange Group (LSEG) Provided data, currentlyRevolution MedicinesThe market value is approximately227Billion US dollars.

●$2.2 Billion Acquisition of RAPT! GSK Makes Bold Bet on China-Originated Innovative Drugs

●$500 Million! Pfizer Adds Another BD Collaboration

●Vice President of Time-Honored Pharmaceutical Company Resigns, Annual Salary 1.0758 Million Yuan